Sex-Disaggregated Mental Health Data and Digital Biomarkers for Women's Health Research

Mential operates Europe's most clinically validated precision mental health platform for women, with programmes covering the full female life course: maternity and postpartum, menopause, burnout, endometriosis/PCOS, caregiver burden, and body image. The platform generates 1,300+ FHIR-structured sex-disaggregated digital biomarkers from real-world multimodal data, providing a unique research infrastructure for understanding sex and gender-specific mechanisms in mental and physical health.

What Mential contributes to a DISEASE-11 or women's health consortium:

• Validated sex-disaggregated datasets: longitudinal, real-world data from 50,000+ women across mental health conditions with documented clinical outcomes.

• - Digital biomarkers for hormonal and psychological interactions: continuous monitoring capturing emotional, behavioural and physiological markers linked to reproductive health stages.

• - 67% greater efficacy than traditional therapy in women-specific programmes, with 92% programme completion and ROI of 4.2x per euro invested.

• - FHIR-native data infrastructure: interoperable, EHDS 2027-ready platform enabling cross-country data sharing and multisite research.

• - Specific clinical programmes: postpartum depression, perinatal anxiety, menopausal mood disorders, burnout in working mothers and professional caregivers.

Mential's approach treats women's mental health as a measurable, dynamic system linked to hormonal cycles, life transitions and social determinants — generating the type of longitudinal, sex-specific evidence that is systematically absent from existing research.

We are seeking a consortium coordinator or lead clinical/academic partner specialised in women's health, reproductive medicine or gender medicine for a HORIZON-HLTH-2026-01-DISEASE-11 proposal. Mential acts as the digital health technology and real-world evidence partner.